Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Spoiled milk: an experimental examination of bias against mothers who breastfeed.

Smith JL, Hawkinson K, Paull K.

Pers Soc Psychol Bull. 2011 Jul;37(7):867-78. doi: 10.1177/0146167211401629. Epub 2011 Mar 18.

PMID:
21421768
2.
3.

Is forced expiratory volume in one second the best measure of severity in childhood asthma?

Spahn JD, Cherniack R, Paull K, Gelfand EW.

Am J Respir Crit Care Med. 2004 Apr 1;169(7):784-6. Epub 2004 Jan 30. Review. No abstract available.

PMID:
14754761
4.

Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.

Voeller DM, Grem JL, Pommier Y, Paull K, Allegra CJ.

Cancer Chemother Pharmacol. 2000;45(5):409-16.

PMID:
10803925
5.

Mining and visualizing large anticancer drug discovery databases.

Shi LM, Fan Y, Lee JK, Waltham M, Andrews DT, Scherf U, Paull KD, Weinstein JN.

J Chem Inf Comput Sci. 2000 Mar-Apr;40(2):367-79.

PMID:
10761142
6.

The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.

Koo HM, Gray-Goodrich M, Kohlhagen G, McWilliams MJ, Jeffers M, Vaigro-Wolff A, Alvord WG, Monks A, Paull KD, Pommier Y, Vande Woude GF.

J Natl Cancer Inst. 1999 Feb 3;91(3):236-44.

PMID:
10037101
7.

Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.

Strumberg D, Pommier Y, Paull K, Jayaraman M, Nagafuji P, Cushman M.

J Med Chem. 1999 Feb 11;42(3):446-57.

PMID:
9986716
8.

Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles.

Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, Bates S, Fojo T.

Mol Pharmacol. 1998 Nov;54(5):802-14.

PMID:
9804615
9.

Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo.

Bradshaw TD, Shi DF, Schultz RJ, Paull KD, Kelland L, Wilson A, Garner C, Fiebig HH, Wrigley S, Stevens MF.

Br J Cancer. 1998 Aug;78(4):421-9.

10.

Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.

Kohlhagen G, Paull KD, Cushman M, Nagafuji P, Pommier Y.

Mol Pharmacol. 1998 Jul;54(1):50-8.

PMID:
9658189
11.

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF.

Science. 1998 May 1;280(5364):734-7.

12.

Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogues.

Shi LM, Fan Y, Myers TG, O'Connor PM, Paull KD, Friend SH, Weinstein JN.

J Chem Inf Comput Sci. 1998 Mar-Apr;38(2):189-99.

PMID:
9538518
13.

2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.

Bradshaw TD, Wrigley S, Shi DF, Schultz RJ, Paull KD, Stevens MF.

Br J Cancer. 1998 Mar;77(5):745-52.

14.
15.

The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.

Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA.

Anticancer Drug Des. 1997 Oct;12(7):533-41. Review. No abstract available.

PMID:
9365500
16.

Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.

Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE.

J Natl Cancer Inst. 1997 Oct 15;89(20):1505-15.

PMID:
9337347
17.

Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines.

Moscow JA, Connolly T, Myers TG, Cheng CC, Paull K, Cowan KH.

Int J Cancer. 1997 Jul 3;72(1):184-90.

18.

P-glycoprotein substrates and antagonists cluster into two distinct groups.

Scala S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B, Lee JS, Elgemeie GH, Stein WD, Bates SE.

Mol Pharmacol. 1997 Jun;51(6):1024-33.

PMID:
9187269
19.

Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines.

Freije JM, Lawrence JA, Hollingshead MG, De la Rosa A, Narayanan V, Grever M, Sausville EA, Paull K, Steeg PS.

Nat Med. 1997 Apr;3(4):395-401.

PMID:
9095172
20.

A protein expression database for the molecular pharmacology of cancer.

Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, Paull KD, Sausville EA, Weinstein JN.

Electrophoresis. 1997 Mar-Apr;18(3-4):647-53.

PMID:
9150955
21.

An information-intensive approach to the molecular pharmacology of cancer.

Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD.

Science. 1997 Jan 17;275(5298):343-9.

PMID:
8994024
22.
23.

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

Koo HM, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, Alvord WG, Oie HK, Gazdar AF, Paull KD, Zarbl H, Vande Woude GF.

Cancer Res. 1996 Nov 15;56(22):5211-6.

24.

Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.

Cleaveland ES, Zaharevitz DW, Kelley JA, Paull K, Cooney DA, Ford H Jr.

Biochem Biophys Res Commun. 1996 Jun 25;223(3):654-9.

PMID:
8687451
25.

Studies on the mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblasts.

Barchi JJ Jr, Cooney DA, Ahluwalia GS, Gharehbaghi K, Covey JM, Hochman I, Paull KD, Jayaram HN.

J Exp Ther Oncol. 1996 May;1(3):191-203.

PMID:
9414404
26.

Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.

Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD.

J Natl Cancer Inst. 1996 Mar 6;88(5):259-69.

PMID:
8614004
27.

Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin.

Hamel E, Lin CM, Plowman J, Wang HK, Lee KH, Paull KD.

Biochem Pharmacol. 1996 Jan 12;51(1):53-9.

PMID:
8534268
28.

Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.

Gupta M, Abdel-Megeed M, Hoki Y, Kohlhagen G, Paull K, Pommier Y.

Mol Pharmacol. 1995 Oct;48(4):658-65.

PMID:
7476891
29.

Azatoxin derivatives with potent and selective action on topoisomerase II.

Leteurtre F, Sackett DL, Madalengoitia J, Kohlhagen G, MacDonald T, Hamel E, Paull KD, Pommier Y.

Biochem Pharmacol. 1995 May 11;49(9):1283-90.

PMID:
7763310
30.

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T.

J Clin Invest. 1995 May;95(5):2205-14.

31.

Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program.

Cleaveland ES, Monks A, Vaigro-Wolff A, Zaharevitz DW, Paull K, Ardalan K, Cooney DA, Ford H Jr.

Biochem Pharmacol. 1995 Mar 30;49(7):947-54.

PMID:
7741767
32.

Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents.

van Osdol WW, Myers TG, Paull KD, Kohn KW, Weinstein JN.

J Natl Cancer Inst. 1994 Dec 21;86(24):1853-9.

PMID:
7990160
33.

Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.

Gharehbaghi K, Sreenath A, Hao Z, Paull KD, Szekeres T, Cooney DA, Krohn K, Jayaram HN.

Biochem Pharmacol. 1994 Oct 7;48(7):1413-9.

PMID:
7945441
34.

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE.

Mol Pharmacol. 1994 Oct;46(4):627-38.

PMID:
7969041
36.

Design and synthesis of ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro.

Jurayj J, Haugwitz RD, Varma RK, Paull KD, Barrett JF, Cushman M.

J Med Chem. 1994 Jul 8;37(14):2190-7.

PMID:
8035426
37.

Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action.

Koutsoukos AD, Rubinstein LV, Faraggi D, Simon RM, Kalyandrug S, Weinstein JN, Kohn KW, Paull KD.

Stat Med. 1994 Mar 15-Apr 15;13(5-7):719-30.

PMID:
8023045
38.

Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.

Gharehbaghi K, Paull KD, Kelley JA, Barchi JJ Jr, Marquez VE, Cooney DA, Monks A, Scudiero D, Krohn K, Jayaram HN.

Int J Cancer. 1994 Mar 15;56(6):892-9.

PMID:
7907081
39.

New antineoplastic aza-phospholipids - synthesis, in-vitro cytotoxicity and differential cellular-sensitivity against 70 human tumor-cell lines.

Principe P, Broquet C, Paull K, Grever M, Coulomb H, Huchet M, Menciahuerta J, Braquet P.

Int J Oncol. 1994 Jan;4(1):29-36.

PMID:
21566885
40.

Reversal of multidrug resistance.

Bates SE, Zhan Z, Dickstein B, Lee JS, Scala S, Fojo AT, Paull K, Wilson W.

J Hematother. 1994 Fall;3(3):219-23. Review. No abstract available.

PMID:
7827870
41.

Reversal of multidrug resistance.

Bates SE, Zhan Z, Dickstein B, Lee JS, Scala S, Fojo AT, Paull K, Wilson W.

Prog Clin Biol Res. 1994;389:33-7. Review. No abstract available.

PMID:
7700913
42.

Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.

Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y.

Biochem Pharmacol. 1993 Jun 22;45(12):2449-56.

PMID:
8392342
43.

Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.

Kuo SC, Lee HZ, Juang JP, Lin YT, Wu TS, Chang JJ, Lednicer D, Paull KD, Lin CM, Hamel E, et al.

J Med Chem. 1993 Apr 30;36(9):1146-56.

PMID:
8387598
44.

In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.

Finlay GJ, Marshall E, Matthews JH, Paull KD, Baguley BC.

Cancer Chemother Pharmacol. 1993;31(5):401-6.

PMID:
8381721
45.

Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.

Hendriks HR, Plowman J, Berger DP, Paull KD, Fiebig HH, Fodstad O, Dreef-van der Meulen HC, Henrar RE, Pinedo HM, Schwartsmann G.

Ann Oncol. 1992 Nov;3(9):755-63.

PMID:
1450065
46.

Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.

Jayaram HN, Gharehbaghi K, Jayaram NH, Rieser J, Krohn K, Paull KD.

Biochem Biophys Res Commun. 1992 Aug 14;186(3):1600-6.

PMID:
1354960
47.
48.

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, et al.

Cancer Res. 1992 Jun 1;52(11):3029-34.

49.

Exploratory data analytic techniques to evaluate anticancer agents screened in a cell culture panel.

Hodes L, Paull K, Koutsoukos A, Rubinstein L.

J Biopharm Stat. 1992;2(1):31-48.

PMID:
1300204

Supplemental Content

Support Center